skip to Main Content

5-Year OS Data Favor Nab-Paclitaxel With Gemcitabine Over Gemcitabine Alone for Resected Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
Treatment with nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer showed positive 5-year overall survival (OS) outcomes that were consistent with the primary analysis of the phase 3 APACT clinical trial (NCT01964430) as well as a post hoc analysis.

Back To Top